eIF2C Double Nickase Plasmid (h): sc-400813-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- eIF2C Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- eIF2C Double Nickase Plasmid (h) and eIF2C Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting AGO2. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: eIF2C Antibody (B-3): sc-376696
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
eIF2C Double Nickase Plasmid (h) | sc-400813-NIC | 20 µg | $410.00 | |||
eIF2C Double Nickase Plasmid (h2) | sc-400813-NIC-2 | 20 µg | $410.00 |
Human AGO2 (eIF2C2) encodes Argonaute 2, the catalytic core of the RNA-induced silencing complex (RISC) that binds small RNAs and directs sequence-specific post-transcriptional gene regulation. AGO2 mediates endonucleolytic “slicer” activity for select siRNA and miRNA targets, contributing to mRNA cleavage, translational repression, and mRNA decay. Through these functions it shapes pathways controlling proliferation, differentiation, innate antiviral responses, and stress-adaptive programs. Dysregulated AGO2 expression or RISC activity has been linked to altered miRNA networks observed across multiple cancers and neurological disorders, supporting its use as a mechanistic node for studying RNA silencing and gene regulatory circuitry.
eIF2C Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the AGO2 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within AGO2. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt AGO2 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of AGO2-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.